Kit Roes has been appointed Professor of Biostatistics at Radboud University/Radboud university medical center, with effect from 1 August 2019. Prior to this appointment, Roes was a Professor of Biostatistics and Clinical Trial Methodology at UMC Utrecht for more than 10 years.
Roes is a biostatistician with extensive experience in statistical applications, research and education. He is a noted expert in the field of clinical studies, methodology and quality of clinical research. His research mainly concentrates on innovative designs and the analysis of clinical research for rare disorders, a focus that fits well with the more individual patient-oriented treatment.
Radboud university medical center
At Radboud university medical center, Prof. Roes and his team will further expand the contribution of biostatistics to research. The combination of innovative designs for (clinical) research and the increasing possibilities offered by prediction and modelling offer the opportunity to evaluate new treatments and techniques more efficiently and thus bring them to the patient more quickly.
Educating students about statistics and biostatistics is extremely important to a number of programmes. Roes will participate in that effort by focusing on the innovations that are taking place in that field, including design and the increasing availability of large data sets.
About Kit Roes
Kit Roes (Nijmegen, 1961) studied mathematics at Radboud University. After graduation, he went to work as an adviser at Philips. He gained more than 10 years’ experience in quality improvement at various companies and in various settings. He earned a PhD in a related context, focusing on new statistical methods for process control.
Biostatistics became his focus when he began working at Organon. He now has more than 15 years’ experience in clinical and non-clinical research into drug development and he has contributed to the development and registration of new drugs in various therapeutic areas. He has been a professor at UMC Utrecht for the past 10 years, where he initiated and led the EU project Asterix about methodologies for clinical studies of rare diseases.
Prof. Roes is chair of the Methodology work group at the College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board) and a member of the Biostatistics Working Party at the European Medicines Agency. He is also an adviser to various national initiatives, including the Regulatory Science Netwerk Nederland (Regulatory Science Network Netherlands) and the Regie op Registers voor Dure Geneesmiddelen (control of registrations for expensive drugs). In addition, he is a member/chair of various Data Safety and Monitoring Boards.
Related news items
Dutch Cancer Society Grant received by Annemiek van Spriel and Laia Querol-Cano23 September 2020
Annemiek van Spriel and Laia Querol-Cano received a Dutch Cancer Society Grant of 700K euros to study the cancer cell surface in immunotherapy.read more
Tumor cells stimulate lipid biosynthesis in macrophages23 September 2020
RIMLS researchers wrote in the Journal for ImmunoTherapy of Cancer that improved lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics.read more
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genomics of Neurodevelopmental Disorders17 September 2020
Annette Schenck has been appointed professor of Translational Genomics of Neurodevelopmental Disorders. with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more